These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 10505071

  • 1. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep 10; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract] [Full Text] [Related]

  • 2. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D, Frey FJ, Ferrari P.
    Praxis (Bern 1994); 2000 Dec 07; 89(49):2073-6. PubMed ID: 11190849
    [Abstract] [Full Text] [Related]

  • 3. [Effect of aldosterone antagonism in heart failure: pharmacotherapeutic options].
    Diercks GF, Overdiek JW, van Veldhuisen DJ.
    Ned Tijdschr Geneeskd; 2001 Feb 03; 145(5):204-8. PubMed ID: 11219145
    [Abstract] [Full Text] [Related]

  • 4. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS, Cruz LS, Domingues GS, Souza CA.
    Expert Opin Drug Saf; 2005 Jul 03; 4(4):677-88. PubMed ID: 16011447
    [Abstract] [Full Text] [Related]

  • 5. [Blocking of aldosterone receptors reduces the risk of events in patients with severe cardiac failure].
    Opasich C.
    Ital Heart J Suppl; 2000 Mar 03; 1(3):425-6. PubMed ID: 10815276
    [No Abstract] [Full Text] [Related]

  • 6. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J.
    N Engl J Med; 1999 Sep 02; 341(10):709-17. PubMed ID: 10471456
    [Abstract] [Full Text] [Related]

  • 7. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J, Fraccarollo D.
    Minerva Cardioangiol; 2003 Apr 02; 51(2):155-64. PubMed ID: 12783071
    [Abstract] [Full Text] [Related]

  • 8. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA.
    N Engl J Med; 2004 Aug 05; 351(6):543-51. PubMed ID: 15295047
    [Abstract] [Full Text] [Related]

  • 9. An old drug provides surprising benefits for heart-failure patients.
    Harv Heart Lett; 1999 Dec 05; 10(4):5-7. PubMed ID: 10564892
    [No Abstract] [Full Text] [Related]

  • 10. Aldosterone and spironolactone in heart failure.
    Weber KT.
    N Engl J Med; 1999 Sep 02; 341(10):753-5. PubMed ID: 10471464
    [No Abstract] [Full Text] [Related]

  • 11. [Anti-aldosterone therapy in severe heart failure].
    van Guldener C, Donker AJ.
    Ned Tijdschr Geneeskd; 1999 Aug 21; 143(34):1724-6. PubMed ID: 10494316
    [Abstract] [Full Text] [Related]

  • 12. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C, Wani M, Steward J, O'Mahony MS.
    Age Ageing; 2005 Jul 21; 34(4):395-8. PubMed ID: 15955761
    [No Abstract] [Full Text] [Related]

  • 13. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 21; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 14. Lack of efficacy of low-dose spironolactone as adjunct treatment to conventional congestive heart failure treatment in dogs.
    Schuller S, Van Israël N, Vanbelle S, Clercx C, McEntee K.
    J Vet Pharmacol Ther; 2011 Aug 21; 34(4):322-31. PubMed ID: 20950346
    [Abstract] [Full Text] [Related]

  • 15. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP, Aaronson KD, Koelling TM.
    Am Heart J; 2004 Dec 21; 148(6):971-8. PubMed ID: 15632880
    [Abstract] [Full Text] [Related]

  • 16. Spironolactone in patients with heart failure.
    Vanpee D, Swine C.
    N Engl J Med; 2000 Jan 13; 342(2):133; author reply 133-4. PubMed ID: 10636753
    [No Abstract] [Full Text] [Related]

  • 17. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ.
    Clin J Am Soc Nephrol; 2006 Mar 13; 1(2):256-62. PubMed ID: 17699214
    [Abstract] [Full Text] [Related]

  • 18. Spironolactone in left-sided heart failure: how does it fit in?
    Margo KL, Luttermoser G, Shaughnessy AF.
    Am Fam Physician; 2001 Oct 15; 64(8):1393-8. PubMed ID: 11681781
    [Abstract] [Full Text] [Related]

  • 19. Spironolactone and ACE inhibition in chronic renal failure.
    Almirall J, Lopez T.
    N Engl J Med; 2002 Feb 07; 346(6):456-7. PubMed ID: 11837270
    [No Abstract] [Full Text] [Related]

  • 20. Aldosterone antagonists in congestive heart failure.
    Soberman J, Chafin CC, Weber KT.
    Curr Opin Investig Drugs; 2002 Jul 07; 3(7):1024-8. PubMed ID: 12186262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.